Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants

Aim: This study was undertaken to assess the immunogenicity, reactogenicity and safety of two doses of an oral live-attenuated human rotavirus vaccine, strain RIX4414 (Rotarix™) in an Indian setting. Patients and Methods: Healthy infants (N=363), approximately 8 weeks of age were enrolled to receive two doses of RIX4414 vaccine (n=182) or placebo (n=181) separated by one month. To assess the immune response, blood samples were taken before vaccination and one month post-dose 2 of RIX4414/placebo. Solicited symptoms were collected for 8-days post each dose and safety data was collected throughout the study. Results: The seroconversion rate observed one month post-dose 2 in the RIX4414 group 58.3% [95% CI: 48.7; 67.4] was significantly higher when compared to the placebo group 6.3%; [95% CI: 2.5; 12.5]. The reactogenicity and safety profile was similar for both groups. Conclusions: Two doses of RIX4414 (Rotarix™) were immunogenic, had a good safety profile and were well-tolerated when administered to healthy Indian infants.

[1]  A. Steele,et al.  Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. , 2010, Vaccine.

[2]  D. Sack,et al.  Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. , 2009, Vaccine.

[3]  Progress towards interrupting wild poliovirus transmission worldwide, 2008. , 2009, Releve epidemiologique hebdomadaire.

[4]  Y. Paul.  OPV cannot eradicate polio from India: do we need any further evidence? , 2008, Vaccine.

[5]  Felix Espinoza,et al.  Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study , 2008, The Lancet.

[6]  T. Vesikari,et al.  Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study , 2007, The Lancet.

[7]  H. Greenberg,et al.  Immunity and correlates of protection for rotavirus vaccines. , 2006, Vaccine.

[8]  T. Vesikari,et al.  Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. , 2006, The New England journal of medicine.

[9]  D. Bernstein,et al.  A rotavirus vaccine for infants: the Asian experience. , 2006, Annals of the Academy of Medicine, Singapore.

[10]  A. Linhares,et al.  Evaluation of Safety, Immunogenicity and Efficacy of an Attenuated Rotavirus Vaccine, RIX4414: A Randomized, Placebo-Controlled Trial in Latin American Infants , 2005, The Pediatric infectious disease journal.

[11]  T. Vesikari,et al.  Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. , 2004, Vaccine.

[12]  S. John,et al.  Serological response to early measles vaccination. , 2004, Journal of tropical pediatrics.

[13]  Philippe Duclos,et al.  The global burden of measles in the year 2000--a model that uses country-specific indicators. , 2003, The Journal of infectious diseases.

[14]  Mark A. Miller,et al.  Global Illness and Deaths Caused by Rotavirus Disease in Children , 2003, Emerging infectious diseases.

[15]  J. Mahanta,et al.  Rotavirus associated acute diarrhoea in hospitalized children in Dibrugarh, north-east India. , 2003, Indian journal of pathology & microbiology.

[16]  R. Glass,et al.  Safety and immunogenicity of tetravalent rhesus-based rotavirus vaccine in Bangladesh , 2001, The Pediatric infectious disease journal.

[17]  R. Glass,et al.  Epidemiology of rotavirus in India , 2001, Indian journal of pediatrics.

[18]  J. Bryce,et al.  Reducing deaths from diarrhoea through oral rehydration therapy. , 2000, Bulletin of the World Health Organization.

[19]  S. M. Hewitt,et al.  Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 1999, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[20]  D. Bernstein,et al.  Protection against rotavirus disease after natural rotavirus infection. US Rotavirus Vaccine Efficacy Group. , 1994, The Journal of infectious diseases.